What is Pion?
Founded in 1996 with roots extending back to 1989, Pion has established itself as a critical partner for the pharmaceutical industry. The company specializes in providing high-precision testing instruments and scientific expertise that facilitate the development of novel therapeutic products. Central to its market position is the Rainbow in situ fiber-optics UV measurement technology, an asset acquired in 2002 that remains a cornerstone of its product portfolio. Pion operates at the intersection of advanced material science and drug discovery, offering solutions that enable researchers to generate reliable, actionable data throughout the product lifecycle. Its long-standing history of innovation, bolstered by the 2011 acquisition by Mike and Sharon Kelly, has allowed the firm to maintain a competitive edge in a highly regulated and technically demanding market.
How much funding has Pion raised?
Pion has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Pion
PPP
Public-Private Partnership
What's next for Pion?
With this late-stage capital injection, Pion is expected to accelerate its strategic roadmap, focusing on the integration of next-generation analytical techniques into its existing platform. The company is likely to prioritize the scaling of its research support services and the enhancement of its fiber-optics measurement capabilities to meet the evolving needs of global drug developers. As the pharmaceutical landscape shifts toward more complex molecular entities, Pion's commitment to providing trusted, science-based data will be instrumental in maintaining its trajectory as a vital infrastructure provider. Future growth will likely involve deepening its market penetration and exploring new applications for its proprietary testing methodologies in emerging therapeutic areas.
See full Pion company page
